Date: 2017-10-18
Type of information: Licensing agreement
Compound: lipid nanoparticle (LNP) technology
Company: Arbutus Biopharma (Canada) Gritstone Oncology (USA - CA)
Therapeutic area: Cancer - Oncology
Type agreement: licensing
Action mechanism:
- RNAi. Lipid Nanoparticle (LNP) technology is a RNAi delivery technology. It allows RNAi drugs to be encapsulated in tiny particles made of lipids. These tiny particles – LNP – travel through the bloodstream to target tissues. They are designed to stay in the circulation long enough to accumulate at disease sites, such as the liver or cancerous tumors. Through a process called endocytosis, cells take up the LNPs which allows them to migrate into the cell. The LNPs then undergo an interaction within the cell and the RNAi trigger molecules are released, mediating RNAi.
Disease:
Details:
- • On October 18, 2017, Arbutus Biopharma and Gritstone Oncology announced a collaboration and license agreement. Arbutus is deploying its proprietary lipid nanoparticle (LNP) technology to deliver Gritstone’s RNA-based neoantigen immunotherapy products.
- Under the terms of this license agreement, Gritstone obtains worldwide access to Arbutus’ portfolio of proprietary and clinically validated LNP products and associated intellectual property. The license is specifically directed to the novel RNA-based platform for neoantigen immunotherapies.
Financial terms:
- Gritstone will pay Arbutus an upfront payment, payments for achievement of development, regulatory, and commercial milestones, as well as royalties. In addition, Gritstone will reimburse Arbutus for conducting technology development and providing manufacturing and regulatory support for Gritstone’s product candidates.
Latest news:
Is general: Yes
